ES2393144T3 - Uso de riboflavina en el tratamiento de la hipertensión - Google Patents

Uso de riboflavina en el tratamiento de la hipertensión Download PDF

Info

Publication number
ES2393144T3
ES2393144T3 ES08715988T ES08715988T ES2393144T3 ES 2393144 T3 ES2393144 T3 ES 2393144T3 ES 08715988 T ES08715988 T ES 08715988T ES 08715988 T ES08715988 T ES 08715988T ES 2393144 T3 ES2393144 T3 ES 2393144T3
Authority
ES
Spain
Prior art keywords
riboflavin
blood pressure
mthfr
product
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08715988T
Other languages
English (en)
Spanish (es)
Inventor
Mary Ward
Helene Mcnulty
Geraldine Horigan
Sean Strain
John Scott
John Purvis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WESTERN HEALTH AND SOCIAL CARE TRUST
University of Ulster
Trinity College Dublin
Original Assignee
WESTERN HEALTH AND SOCIAL CARE TRUST
University of Ulster
Trinity College Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WESTERN HEALTH AND SOCIAL CARE TRUST, University of Ulster, Trinity College Dublin filed Critical WESTERN HEALTH AND SOCIAL CARE TRUST
Application granted granted Critical
Publication of ES2393144T3 publication Critical patent/ES2393144T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES08715988T 2007-02-23 2008-02-22 Uso de riboflavina en el tratamiento de la hipertensión Active ES2393144T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0703514.0A GB0703514D0 (en) 2007-02-23 2007-02-23 Use of riboflavin
GB0703514 2007-02-23
PCT/EP2008/001437 WO2008101724A1 (en) 2007-02-23 2008-02-22 Use of riboflavin in the treatment of hypertension

Publications (1)

Publication Number Publication Date
ES2393144T3 true ES2393144T3 (es) 2012-12-18

Family

ID=37945596

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08715988T Active ES2393144T3 (es) 2007-02-23 2008-02-22 Uso de riboflavina en el tratamiento de la hipertensión

Country Status (10)

Country Link
US (1) US20100324019A1 (cg-RX-API-DMAC7.html)
EP (1) EP2139488B1 (cg-RX-API-DMAC7.html)
JP (1) JP5577100B2 (cg-RX-API-DMAC7.html)
CN (1) CN101678030B (cg-RX-API-DMAC7.html)
CA (1) CA2679217C (cg-RX-API-DMAC7.html)
EA (1) EA019281B1 (cg-RX-API-DMAC7.html)
ES (1) ES2393144T3 (cg-RX-API-DMAC7.html)
GB (1) GB0703514D0 (cg-RX-API-DMAC7.html)
MX (1) MX2009009020A (cg-RX-API-DMAC7.html)
WO (1) WO2008101724A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358541B (es) * 2012-08-16 2018-08-24 Critical Care Diagnostics Inc Metodos para predecir el riesgo de desarrollar hipertension.
CN103721259A (zh) * 2014-01-07 2014-04-16 深圳奥萨医药有限公司 血管紧张素ⅱ受体阻断剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物
CN109295216A (zh) * 2018-11-06 2019-02-01 宁波艾捷康宁生物科技有限公司 预测高血压个体化药物药效的snp位点和检测试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
ATE68704T1 (de) * 1986-12-18 1991-11-15 Bauer Kurt Heinz Gegenueber lichteinfluss stabilisiertes nifedipin- konzentrat und verfahren zu seiner herstellung.
US6485959B1 (en) * 1998-10-07 2002-11-26 Cedars Sinai Medical Center Cell preconditioning and cryopresevation medium
CN1136895C (zh) * 2001-05-24 2004-02-04 魏振鸣 一种治疗冠心病的药物
WO2006085128A1 (en) * 2005-02-09 2006-08-17 Wockhardt Limited Cardiovascular therapeutic combinations
US7838526B2 (en) * 2005-08-05 2010-11-23 Esther Baldinger Method of treating neurological disorders

Also Published As

Publication number Publication date
US20100324019A1 (en) 2010-12-23
CA2679217C (en) 2016-05-17
CN101678030B (zh) 2013-06-05
EA019281B1 (ru) 2014-02-28
WO2008101724A8 (en) 2009-10-08
JP2010519235A (ja) 2010-06-03
JP5577100B2 (ja) 2014-08-20
CN101678030A (zh) 2010-03-24
GB0703514D0 (en) 2007-04-04
MX2009009020A (es) 2010-02-17
EP2139488B1 (en) 2012-08-15
EA200901145A1 (ru) 2010-02-26
EP2139488A1 (en) 2010-01-06
CA2679217A1 (en) 2008-08-28
WO2008101724A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
RU2318517C2 (ru) Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент
TWI630924B (zh) 使用包含微脂體伊立替康(irinotecan)的組合療法治療胰臟癌的方法
ES2981521T3 (es) Compuestos y procedimientos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales
Grünwald et al. Practical management of everolimus-related toxicities in patients with advanced solid tumors
JP2010518169A (ja) 心血管疾患の処置のためのラノラジンの使用
US20190307791A1 (en) Use of ferric citrate in the treatment of and the reduction of mortality and morbidity related to adverse cardiac events in chronic kidney disease patients
Li et al. Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor
BR112021005518A2 (pt) métodos para tratar distúrbios mieloproliferativos
Trzos et al. Myocardial infarction in young people
CA3113376A1 (en) Compositions for reducing serum uric acid
KR20200013644A (ko) 간세포 암종의 치료
KR20250078897A (ko) 알도스테론 신타아제 저해제인 박스드로스타트를 이용한 고혈압 치료 방법
CA2679217C (en) Use of riboflavin in the treatment of hypertension
US20190201508A1 (en) Methods for treating cancers using ace inhibitors, arb, or celecoxib and olmesartan
JPH11507012A (ja) 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療
US20220160739A1 (en) Methods for treating subjects with chronic kidney disease
WO2024173768A1 (en) Compositions and methods of using eflornithine
KR20080012896A (ko) 췌장염 예방 및 치료제
Mizumura et al. Vasovagal reaction and ischemic colitis following blood donation
Liau et al. Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in Chinese patients
Villanueva et al. Probable association between ziprasidone and worsening hypertension
Mikhailova et al. Pharmacokinetics of Angiotensin-Converting Enzyme Inhibitors in Elderly Patients with Arterial Hypertension
MX2014012001A (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek.
Rolfo et al. Adverse event management in anaplastic lymphoma kinase-positive non-small cell lung cancer
Cacciola et al. Effect of anagrelide on JAK2 mutational status in patients with essential thrombocythemia